{
    "organizations": [],
    "uuid": "8daf9a106d3b5b72161164815e4a28d3a142b702",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-paratek-pharmaceuticals-reports-q1/brief-paratek-pharmaceuticals-reports-q1-loss-per-share-0-91-idUSASC0A0XU",
    "ord_in_thread": 0,
    "title": "Paratek Pharmaceuticals Reports Q1 Loss Per Share $0.91",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 9 (Reuters) - Paratek Pharmaceuticals Inc:\n* PARATEK PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS\n* Q1 LOSS PER SHARE $0.91 * Q1 EARNINGS PER SHARE VIEW $-0.91 â€” THOMSON REUTERS I/B/E/S\n* ON TRACK FOR A Q1 2019 OMADACYCLINE U.S. LAUNCH * PREPARING FOR ADVISORY COMMITTEE MEETING, EXPECTED IN LATE SUMMER 2018, TO REVIEW OMADACYCLINE APPLICATIONS\n* PARATEK - AS OF MARCH 31, 2018, HAD CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $184.3 MILLION\n* PARATEK PHARMACEUTICALS - CURRENTLY EXPECTS TO BE ABLE TO FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS THROUGH Q1 2021 (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-05-09T19:46:00.000+03:00",
    "crawled": "2018-05-09T15:03:11.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "paratek",
        "pharmaceutical",
        "inc",
        "paratek",
        "pharmaceutical",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "track",
        "q1",
        "omadacycline",
        "launch",
        "preparing",
        "advisory",
        "committee",
        "meeting",
        "expected",
        "late",
        "summer",
        "review",
        "omadacycline",
        "application",
        "paratek",
        "march",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "million",
        "paratek",
        "pharmaceutical",
        "currently",
        "expects",
        "able",
        "fund",
        "operating",
        "expense",
        "capital",
        "expenditure",
        "requirement",
        "q1"
    ]
}